Bristol-Myers: FDA seeks data on transplant drug
May 02, 2010 at 05:59 AM EDT
Bristol-Myers Squibb Co. receives the U.S. Food and Drug Administration's complete-response letter regarding its biologics-license application to market belatacept for people who've received kidney transplants.
